The criterion validity of general and antisocial personality disorder-specific criterion A in the alternative model of personality disorders: A scoping review and meta-analysis.

Personal DisordApr 13, 2026 (epub)
Clinical ResearchPsychiatry

Nathan Akoka, Ashley L Dunne, Michael Trood et al.

✦ AI-curated · Sources linked

In 30 seconds

This scoping review and meta-analysis examined the criterion validity of general Levels of Personality Functioning Scale (LPFS) measures and antisocial personality disorder (ASPD)-specific measures for assessing ASPD, psychopathy, antisocial behavior, and aggression. The review identified 32 studies. Pooled associations between LPFS measures and Section II ASPD were strong; associations with psychopathy varied by rating method, while links with aggression and antisocial behavior were weak to moderate. ASPD-specific measures showed moderate associations with Section II ASPD and large associations with psychopathy.

Key findings

  • Pooled associations between self-report and clinician-rated LPFS measures and Section II ASPD were strong.
  • LPFS associations with psychopathy were moderate for self-report measures and weak for clinician-rated measures.
  • LPFS associations with aggression and antisocial behavior were weak to moderate.
  • ASPD-specific impairment measures had moderate associations with Section II ASPD and large associations with psychopathy.

Why it matters

Criterion A assessment may capture antisociality differently depending on the measure and the construct being assessed. The review highlights that general personality-functioning measures and ASPD-specific instruments provide complementary information, relevant to diagnostic assessment and to violence risk formulation and management.

What to keep in mind

The review found variable validity across measures and outcomes, so pooled findings do not support relying on a single measure in isolation.

Source

Published in Personal Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.